Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Pfizer’s Braftovi to command 42% share of BRAF inhibitors melanoma market by 2028, forecasts GlobalData

Since Roche‘s Zelboraf gained (vemurafenib) FDA approval in 2011, significant strides have been made in BRAF-targeted cancer therapies, underscoring the significance of combating BRAF mutations in melanoma. Against this backdrop, Pfizer‘s Braftovi (encorafenib) is positioned to secure a dominant 42% share of the BRAF inhibitors market for melanoma by 2028, underscoring its pivotal role in […]
Read more

FDA approval for Madrigal’s Rezdiffra in metabolic dysfunction-associated steatohepatitis will set precedence for approval of future pipeline agents, says GlobalData

Following the news on 14 March 2024 that FDA has granted accelerated approval for Madrigal Pharmaceuticals’ thyroid hormone receptor (THR)-β agonist Rezdiffra (resmetirom) for the treatment of patients with metabolic dysfunction-associated steatohepatitis (MASH), also known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis; Sravani Meka MPH, Senior Pharma Analyst at GlobalData, a leading […]
Read more

Pharmaceutical companies pursuit of patient empowerment calls for enhanced effort, says GlobalData

Pharmaceutical companies are increasingly recognizing the importance of empowering patients to take charge of their health. However, there is still room for improvement in supporting patients. This underscores the need for greater efforts to meet patient needs and enhance engagement, says GlobalData, a leading data and analytics company. GlobalData’s latest survey-based* Thematic Intelligence report, “Patient […]
Read more

Cell therapies show promise for addressing Parkinson’s disease non-motor symptoms, says GlobalData

Within the current treatments of Parkinson’s disease (PD) there is an unmet need for addressing the loss of dopaminergic neurons and non-motor symptoms. At the AD/PD 2024 International Conference on Alzheimer’s and Parkinson’s Diseases, BlueRock Therapeutics (a subsidiary of Bayer) presented positive results from their Phase I clinical trial of the gene-modified cell therapy Bemdaneprocel […]
Read more

Biomarkers becoming important for approval of amyotrophic lateral sclerosis therapies, says GlobalData

The recently concluded AD/PD 2024 International Conference on Alzheimer’s Disease (AD) and Parkinson’s Disease (PD) focused on innovative approaches poised to revolutionize the treatment of amyotrophic lateral sclerosis (ALS) and the use of neurochemical biomarkers in ALS drug development. As biomarkers are used for early diagnostics in clinics and as outcome parameters for novel treatment […]
Read more
,

Biotech funding set for recovery in 2024, reveals GlobalData

The biopharmaceutical industry is witnessing a shift in investor sentiment. Despite facing challenges such as declining venture financing and macroeconomic pressures, there exists optimism about a recovery in biotech funding. Healthcare professionals globally express cautious optimism, emphasizing the importance of alternative funding avenues and industry partnerships. This dynamic landscape sets the stage for potential growth […]
Read more

Diagnosed incident cases of non-small cell lung cancer across 8MM to reach 1.46 million in 2032, forecasts GlobalData

The diagnosed incident cases of non-small cell lung cancer (NSCLC) in the eight major markets (8MM*) are projected to increase at an annual growth rate (AGR) of 3.33% from 1.01 million in 2022 to 1.46 million in 2032, forecasts GlobalData, a leading data and analytics company. GlobalData’s latest report, “Non-Small Cell Lung Cancer (NSCLC): Epidemiology […]
Read more

Opdivo to face direct competition with Keytruda and Padcev combination in bladder cancer space, says GlobalData

Bristol Myers Squibb’s Opdivo was recently granted FDA approval in combination with cisplatin and gemcitabine as a first-line treatment for metastatic urothelial carcinoma (mUC). With this approval, Opdivo positions itself to compete with Merck & Co’s immune checkpoint inhibitor (ICI) Keytruda in combination with Astellas and Pfizer’s Padcev, a nectin-4-directed antibody-drug conjugate (ADC). The Keytruda/Padcev […]
Read more

TauRx’s HMTM could become first oral DMT targeting Tau for Alzheimer’s disease, says GlobalData

Following the Phase III LUCIDITY trial (NCT03446001) results announced by TauRx at the AD/PD 2024 International Conference on Alzheimer’s and Parkinson’s Diseases, for hydromethylthionine mesylate (HMTM); Philippa Salter, Senior Neurology Analyst at GlobalData, a leading data and analytics company, offers her view: “At AD/PD 2024, TauRx announced that it has initiated regulatory discussions with both […]
Read more

Oncology dominates CRISPR landscape, reveals GlobalData

The Medicines and Healthcare products Regulatory Agency (MHRA) approved Vertex’s exagamglogene autotemcel (Casgevy) in late 2023. Subsequently, it became the inaugural CRISPR-based drug for the hematological indications beta thalassemia and sickle cell disease (SCD). Despite this approval, the CRISPR landscape is dominated by oncology, which accounts for 30% of all active CRISPR drugs. The precision […]
Read more

Patient and healthcare professional relationship crucial for effective care, says GlobalData

In healthcare, the foundation of effective care lies in the trust between patients and healthcare professionals (HCPs). Central to this trust is the quality of information conveyed by HCPs, which directly impacts patient satisfaction and empowerment. A robust patient-physician relationship hinges on patients’ confidence in the knowledge and expertise of their healthcare providers, underscoring the […]
Read more
1 … 21 22 23 24 25 … 108